Leaders in diabetes weigh in at The diaTribe Foundation’s second-annual event in Europe.

Thoughts on democratizing health care, precision medicine, and more from Stanford MedX 2015.

Our top takeaways from the health and medicine edition of the world-famous TED conference.

Plus, how the field of diabetes can learn from the environmental movement.

Saturday, August 27; $10 early bird registration fee

ADA statement of support released at the 2 nd Diabetes Surgery Summit; highlights reversal of diabetes symptoms after surgery for some candidates

Advice for increasing daily activity, the new Fit2Me mobile app, and enthusiasm for the National Diabetes Prevention Program

The diaTribe Foundation’s 2016 gathering shares need for earlier treatment, data integration, prevention, amplifying patient voices, and reducing stigma.

less risk of diabetes complications, lower A1c, improved weight loss and hypoglycemia; led by Novo Nordisk’s Victoza and semaglutide

Our own Kelly Close moderates a panel at SXSW Interactive.

Glucose, food, exercise, and even DIY closed loop on the phone

“We have to create solutions in diabetes that are as addictive as the iPhone.”

Views on FDA regulation, pipeline updates, and first vs. next-generation systems.

LEADER results announced at #2016ADA – compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease. More results...

A standing ovation for Dr. Margaret Powers at ADA last month r Dr. Margaret Powers at ADA last month.

The Annual TCOYD/The diaTribe Foundation Forum Celebrates its 10 th Anniversary in New Orleans

Device Updates from Abbott, Dexcom, Insulet, Medtronic, and Tandem

Research presented at ADA’s 2017 conference shows exciting advances in a host of diabetes drugs – including heart benefits, improved glucose control, lower cholesterol,...

Kelly Close and Adam Brown lead expert panel discussion at The diaTribe Foundation’s second annual diabetes digital health gathering at ADA 2017

The diaTribe Foundation and TCOYD host discussion at ADA focusing on access, outcomes beyond A1c, and future expectations